Drug-induced lupus: clinical spectrum and pathogenesis.
D000107:Acetylation; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D000918:Antibody Specificity; D001327:Autoimmune Diseases / Q000139:chemically induced; D044383:Black People; D001921:Brain / Q000187:drug effects; D002746:Chlorpromazine / Q000009:adverse effects; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D007538:Isoniazid / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000187:drug effects; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000235:genetics; D008297:Male; D008750:Methyldopa / Q000009:adverse effects; D009132:Muscles / Q000187:drug effects; D010641:Phenotype; D011342:Procainamide / Q000009:adverse effects
D000974:Antibodies, Antinuclear; D006830:Hydralazine; D008750:Methyldopa; D011342:Procainamide; D002746:Chlorpromazine; D007538:Isoniazid